Stay updated on PD-1 Combo in Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the PD-1 Combo in Renal Cancer Clinical Trial page.

Latest updates to the PD-1 Combo in Renal Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding the comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma, including an erratum reference.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase II clinical trial for advanced renal cancer and the addition of a new study focusing on the use of autologous D-CIK cells combined with anti-PD-1 antibody. The principal investigator's name, Fangjian Zhou, MD, PhD, has been retained.SummaryDifference29%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to PD-1 Combo in Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 Combo in Renal Cancer Clinical Trial page.